UBS Group
BBP icon

UBS Group’s Virtus Biotech ETF BBP Stock Holding History

UBS Group’s Portfolio BBP Stock Details BBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83 Buy
+1
New +$82 ﹤0.01% 10144
2025
Q2 		– Sell
-488
Closed -$28.6K – 10250
2025
Q1 		$28.6K Buy
488
+241
+98% +$14.8K ﹤0.01% 7978
2024
Q4 		$14.8K Buy
+247
New +$15.6K ﹤0.01% 8068
2024
Q1 		– Sell
-448
Closed -$26K – 9307
2023
Q4 		$26K Buy
+448
New +$22.7K ﹤0.01% 6936
2023
Q2 		– Sell
-175
Closed -$8.62K – 8918
2023
Q1 		$8.62K Sell
175
-894
-84% -$44.9K ﹤0.01% 7709
2022
Q4 		$52.7K Buy
1,069
+139
+15% +$6.65K ﹤0.01% 6730
2022
Q3 		$42K Sell
930
-614
-40% -$28.3K ﹤0.01% 6512
2022
Q2 		$64K Buy
1,544
+1,029
+200% +$40.9K ﹤0.01% 5735
2022
Q1 		$22K Buy
515
+54
+12% +$2.32K ﹤0.01% 7332
2021
Q4 		$23K Buy
461
+431
+1,437% +$21.4K ﹤0.01% 7670
2021
Q3 		$2K Sell
30
-67
-69% -$3.46K ﹤0.01% 8927
2021
Q2 		$5K Sell
97
-1,073
-92% -$56.6K ﹤0.01% 8530
2021
Q1 		$61K Sell
1,170
-1,222
-51% -$68.2K ﹤0.01% 6351
2020
Q4 		$127K Buy
2,392
+882
+58% +$45.2K ﹤0.01% 5532
2020
Q3 		$72K Sell
1,510
-615
-29% -$28.6K ﹤0.01% 5392
2020
Q2 		$101K Buy
2,125
+446
+27% +$19.9K ﹤0.01% 5295
2020
Q1 		$63K Buy
1,679
+233
+16% +$9.63K ﹤0.01% 5634
2019
Q4 		$63K Sell
1,446
-1,764
-55% -$70.8K ﹤0.01% 6228
2019
Q3 		$115K Buy
3,210
+1,112
+53% +$42.6K ﹤0.01% 5688
2019
Q2 		$86K Buy
2,098
+2,024
+2,735% +$83.3K ﹤0.01% 5482
2019
Q1 		$3K Sell
74
-1,163
-94% -$48.7K ﹤0.01% 7322
2018
Q4 		$43K Sell
1,237
-617
-33% -$23.5K ﹤0.01% 6223
2018
Q3 		$84K Buy
1,854
+769
+71% +$34.4K ﹤0.01% 5730
2018
Q2 		$48K Buy
1,085
+55
+5% +$2.33K ﹤0.01% 5984
2018
Q1 		$43K Sell
1,030
-547
-35% -$23K ﹤0.01% 5826
2017
Q4 		$64K Buy
1,577
+1,542
+4,406% +$61.6K ﹤0.01% 5657
2017
Q3 		$1K Sell
35
-57
-62% -$2.28K ﹤0.01% 7557
2017
Q2 		$4K Sell
92
-2,290
-96% -$85.5K ﹤0.01% 7196
2017
Q1 		$90K Sell
2,382
-1,505
-39% -$55.1K ﹤0.01% 5130
2016
Q4 		$127K Buy
+3,887
New +$127K ﹤0.01% 5125
2016
Q3 		– Sell
-1,538
Closed -$41K – 7668
2016
Q2 		$41K Buy
+1,538
New +$40.6K ﹤0.01% 5664
2016
Q1 		– Sell
-1,213
Closed -$37K – 7634
2015
Q4 		$37K Sell
1,213
-218
-15% -$6.61K ﹤0.01% 6108
2015
Q3 		$40K Buy
1,431
+273
+24% +$9.21K ﹤0.01% 6019
2015
Q2 		$41K Sell
1,158
-21
-2% -$690 ﹤0.01% 6168
2015
Q1 		$37K Buy
+1,179
New +$34.5K ﹤0.01% 6319

Other funds holding BBP

Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
PCIA
Prime Capital Investment Advisors Overland Park, Kansas $8.65B AUM 19.52% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MSL
MILLINGTON SECURITIES, LLC Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return

UBS Group's BBP Position: Q1 2026 in Review

UBS Group opened a new position in Virtus Biotech ETF (BBP) in Q1 2026: 1 share worth $83. The stake represents ﹤0.01% of the portfolio and ranks #10144 among its holdings. This is a return to the name: UBS Group previously reported a position in BBP as recently as Q1 2025.

UBS Group first reported a position in BBP in Q1 2015 and has held it in 35 quarters since. The position peaked at $127K in Q4 2020. 26 funds tracked by Wall St. Rank hold BBP as of Q1 2026.

  • UBS Group held 1 share of Virtus Biotech ETF worth $83 as of Q1 2026.
  • Virtus Biotech ETF was a new UBS Group position in Q1 2026.
  • Virtus Biotech ETF made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10144 holding.
  • UBS Group first reported a position in Virtus Biotech ETF in Q1 2015 and has held it in 35 quarters since.
  • UBS Group's Virtus Biotech ETF position peaked at $127K in Q4 2020.
  • 26 funds tracked by Wall St. Rank held Virtus Biotech ETF as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.